VTGN:NASDAQ, Vistagen Therapeutics, Inc.

Why VTGN stock fell on November 20

Vistagen Therapeutics, Inc. fell 12.3% on Friday, November 20, 2026, on 908,858 shares. No headline about VTGN came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

VTGN stock overview

Vistagen Therapeutics, Inc. (VTGN:NASDAQ) closed at $0.164 on November 20, 2026, down 12.33% on the day. The stock trades 96.8% below its 52-week high of $5.14 and 2.3% above its 52-week low of $0.160. Over the past year, it lost 96.4%. Vistagen Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price
$0.164
Day change
-12.33%
Volume
908,858
Average volume
10,304,832
Market cap
7M+
52-week range
$0.160 – $5.14
50-day average
$0.219
200-day average
$0.416

Price action over the past year

In 252 trading sessions since November 20, 2025, VTGN closed higher on 88 days (35%). Its best day was September 23, 2026 (+48.00%) and its worst was December 17, 2025 (-80.28%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

VTGN news

About Vistagen Therapeutics, Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with central nervous system (CNS) diseases. The company's lead product candidate, AV-101, which is in Phase IIa development as a augmentation option for adult patients suffering from treatment-resistant major depressive disorder (TRD). It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary small molecule new chemical entities (NCEs) for its internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and/or liver cells derived from hPSCs. In addition, the company offers CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. It has strategic collaborations with University Health Network, the McEwen Centre for Regenerative Medicine, and the Centre for the Commercialization of Regenerative Medicine for stem cell technology research, development, and cell production; and Norac Pharma, Pharmatek, and Synterys, Inc. to design, produce, and analyze AV...

Similar stocks

Find more stocks like VTGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.